| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
NK3 receptor (tachykinin receptor 3). (S)-Osanetant is a selective antagonist of the NK3 receptor, blocking the effects of the endogenous agonist neurokinin B, which is involved in the regulation of mood, stress responses, and dopamine signaling pathways.
|
|---|---|
| ln Vitro |
As the S-enantiomer of Osanetant, (S)-Osanetant is expected to retain the selective NK3 receptor antagonistic activity of the parent compound. Osanetant is known to block NK3 receptors with high affinity and selectivity over other neurokinin receptors (NK1 and NK2). The S-enantiomer‘s specific in vitro potency and selectivity have not been quantitatively characterized in published literature; however, it is used as a pharmacological reference tool.
|
| ln Vivo |
No specific in vivo efficacy data are reported for (S)-Osanetant separately from the parent compound. Osanetant produces anxiolytic- and antidepressant-like effects in preclinical models and has been studied for the treatment of schizophrenia. The S-enantiomer is expected to share these pharmacological properties, though it may exhibit differences in potency or metabolic stability.
|
| Enzyme Assay |
Cell-free NK3 receptor binding assays are performed using membranes from CHO-K1 cells stably expressing the human NK3 receptor. Membranes are incubated with 0.5-1 nM [125I]-[MePhe7]-neurokinin B and increasing concentrations of (S)-Osanetant (0.01-10,000 nM) in 50 mM Tris-HCl (pH 7.4) containing 4 mM MnCl2, 0.1% BSA, and protease inhibitors for 60-90 min at 25degC. Bound radioactivity is separated by GF/B filtration. IC50 is calculated by nonlinear regression and converted to Ki using the Cheng-Prusoff equation.
|
| Cell Assay |
CHO-K1 cells stably expressing the human NK3 receptor are loaded with a calcium-sensitive fluorescent dye. Cells are pre-incubated with (S)-Osanetant (0.1-10,000 nM) for 10-15 min, followed by stimulation with the NK3 agonist senktide (10-30 nM). Intracellular calcium flux is measured in real-time using a FLIPR. IC50 for antagonism is calculated as the concentration required to inhibit 50% of the senktide-induced calcium response. The antagonistic activity can be confirmed by rightward shifts of the senktide concentration-response curve.
|
| Animal Protocol |
For in vivo studies, (S)-Osanetant would be administered to rodents via intraperitoneal or subcutaneous injection (1-30 mg/kg) or oral gavage. Behavioral assays relevant to anxiety (elevated plus maze, marble burying), depression (forced swim test, tail suspension test), and schizophrenia (prepulse inhibition, amphetamine-induced hyperlocomotion) can be performed. However, published studies typically use the racemate or unspecified enantiomer. (S)-Osanetant itself requires experimental validation.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data are reported for the isolated S-enantiomer. The parent compound Osanetant has a molecular weight of 606.62 (C35H41Cl2N3O2). (S)-Osanetant has the same molecular weight, CAS# 182621-58-5, purity ≥98%. Solubility: DMSO 70 mg/mL (115.39 mM). For in vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (≥2.5 mg/mL). PK parameters (t1/2, Cmax, AUC, F%) are not specified. Storage: powder at -20degC for 3 years, in solvent at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for (S)-Osanetant. The parent compound Osanetant was generally well-tolerated in clinical studies for schizophrenia, with no major safety concerns reported. Standard toxicological assessments (hERG, Ames, repeat-dose toxicity) would be required for clinical development. (S)-Osanetant has not been approved by any regulatory agency and has not progressed to clinical development as a distinct entity.
|
| References | |
| Additional Infomation |
Other information: (S)-Osanetant is a research compound (CAS# 182621-58-5) not FDA-approved. It is the S-enantiomer of Osanetant (SR142801). The compound is available for research use only. It is a valuable tool for stereoselectivity studies of NK3 receptor antagonists. Due to the high cost, it is primarily used for laboratory research to investigate NK3 receptor pharmacology. For research use only.
|
| Molecular Formula |
C35H41CL2N3O2
|
|---|---|
| Molecular Weight |
606.624947309494
|
| Exact Mass |
605.257
|
| CAS # |
182621-58-5
|
| Related CAS # |
Osanetant;160492-56-8
|
| PubChem CID |
9895700
|
| Appearance |
White to off-white solid powder
|
| LogP |
7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
42
|
| Complexity |
897
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)N(C)C1(CCN(CC1)CCC[C@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
|
| InChi Key |
DZOJBGLFWINFBF-UUWRZZSWSA-N
|
| InChi Code |
InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m1/s1
|
| Chemical Name |
N-[1-[3-[(3S)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 70 mg/mL (115.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6485 mL | 8.2424 mL | 16.4848 mL | |
| 5 mM | 0.3297 mL | 1.6485 mL | 3.2970 mL | |
| 10 mM | 0.1648 mL | 0.8242 mL | 1.6485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
